SAB Biotherapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops and commercializes immunotherapies to treat infectious diseases. Read more

6 Followers on Owler
6 Followers on Owler
6 Followers on Owler
6 Followers on Owler

SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops and commercializes immunotherapies to treat infectious diseases. Read more

Eddie J. Sullivan's photo - President & CEO of SAB Biotherapeutics

President & CEO

Eddie J. Sullivan

CEO Approval Rating

89/100

Founded:

2014

Status:

PrivateIndependent Company

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

GeoVax has been one of SAB Biotherapeutics's top competitors. GeoVax's headquarters is in Smyrna, Georgia, and was founded in 2001. GeoVax is in the Health Care Supplies industry. GeoVax generates 52% of SAB Biotherapeutics's revenue.

CEL-SCI is one of SAB Biotherapeutics's top rivals. CEL-SCI is a Public company that was founded in Vienna, Virginia in 1983. CEL-SCI operates in the Biotechnology industry. CEL-SCI has 16 fewer employees vs. SAB Biotherapeutics.

Aduro is perceived as one of SAB Biotherapeutics's biggest rivals. Aduro was founded in 2000, and is headquartered in Berkeley, California. Aduro operates in the Biotechnology industry. Aduro generates $25.6M more revenue vs. SAB Biotherapeutics.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 60 a good estimate for SAB Biotherapeutics's Employee count?

Acquisitions

No recent acquisitions found related to SAB Biotherapeutics

SAB Biotherapeutics Funding History

$3M$4.4M$36.4M$50.8M

Since SAB Biotherapeutics was founded in 2014, it has participated in 6 rounds of funding. In total SAB Biotherapeutics has raised $50.8M. SAB Biotherapeutics' last funding round was on Jul 2020 for a total of $14.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series B
Jul 2020
$14M
Debt - PPP (CARES Act)
Apr 2020
$350K - $1M

U.S. Small Business Administration.

Series A
Dec 2018
$22M
-
Series A
Aug 2018
$10M
-
Grant
Sep 2016
$1.4M
-

Since SAB Biotherapeutics was founded in 2014, it has participated in 6 rounds of funding. In total SAB Biotherapeutics has raised $50.8M. SAB Biotherapeutics' last funding round was on Jul 2020 for a total of $14.0M

Investments

No recent investments found related to SAB Biotherapeutics

SAB Biotherapeutics News

August 21, 2020MarketScreener

SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19

(marketscreener.com) Phase 1b clinical trial will evaluate the safety and pharmacological activity of... See more »
August 13, 2020Contract Pharma

SAB Receives $35.6 Miliion from U.S. DOD

Funds rapid response antibody program to combat COVID-19.... See more »
August 7, 2020Army Technology

Coronavirus company news summary - US DOD funds SAB's DiversitAb Rapid Response Antibody Programme - Huntington Ingalls Industries provides Covid-19 update

7 August The US Department of Defense (DOD) has awarded an additional $35.6m to fund SAB Biotherapeut... See more »
August 6, 2020BioSpace

SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program

SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Res... See more »
May 29, 2020Pharmaceutical Business Review

SAB Biotherapeutics confirms neutralising antibodies to SARS-CoV-2 and begins clinical manufacturing of novel Covid-19 therapeutic candidate

The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next... See more »
April 17, 2020Army Technology

SAB and DoD advance therapeutic drug candidate for Covid-19

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Follow the latest ... See more »

SAB Biotherapeutics Press Releases

Social Media

Headquarters

2301 E 60th St N

Sioux Falls, South Dakota57104

844-268-4239

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

SAB Biotherapeutics is a clinical-stage biopharmaceutical company that develops and commercializes immunotherapies to treat infectious diseases. SAB Biotherapeutics was founded in 2014. SAB Biotherapeutics' headquarters is located in Sioux Falls, Sout...

CEO

SAB Biotherapeutics's President & CEO, Eddie J. Sullivan, currently has an approval rating of 89%. SAB Biotherapeutics's primary competitors are GeoVax, CEL-SCI & Aduro.

Website

sabbiotherapeutics.com

Frequently Asked Questions about SAB Biotherapeutics

  1. When was SAB Biotherapeutics founded?

    SAB Biotherapeutics was founded in 2014
  2. Who is SAB Biotherapeutics's CEO?

    SAB Biotherapeutics's CEO is Eddie J. Sullivan
  3. How much revenue does SAB Biotherapeutics generate?

    SAB Biotherapeutics generates $3.6M in revenue
  4. How much funding does SAB Biotherapeutics have?

    SAB Biotherapeutics has historically raised $50.8M in funding
  1. Where is SAB Biotherapeutics's headquarters?

    SAB Biotherapeutics's headquarters is in Sioux Falls South Dakota, USA
  2. How many employees does SAB Biotherapeutics have?

    SAB Biotherapeutics has 60 employees
  3. What sector does SAB Biotherapeutics operate in?

    SAB Biotherapeutics is in Medical Research & Laboratories
  4. Who are SAB Biotherapeutics's competitors?

    SAB Biotherapeutics's top competitors are GeoVax, CEL-SCI, Aduro